01244.HK
3D Medicines Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 2.61
+3.98%Oct 29, 2026, 12:28 UTC
3D Medicines, Inc. said the phase III REGAL trial of 3D189 (Galinpepimut-S) for acute myeloid leukemia reached its prespecified 80-death event threshold, triggering final analysis.
Source:Oct 29, 2026, 12:28 UTC
SELLAS will lock the database, unblind the study data and conduct the primary-endpoint analysis, then publish preliminary topline results this quarter.
Source:Sep 24, 2026, 11:30 UTC
Luxembourg's Ministry of Health and Social Security reminded women using contraceptives containing desogestrel or etonogestrel not to stop treatment without medical advice, after the PRAC recommended adding meningioma risk to product information.
Source:Aug 20, 2026, 01:46 UTC
On August 20, 2026, Hong Kong-listed biotech stocks surged broadly, with 3D Medicines rising 55%, Everest Medicines rising 50%, CanSino Biologics rising 45%, and other biotech firms gaining sharply.
Source:Aug 18, 2026, 04:35 UTC
3D Medicines announced that the arbitration award in its favor against SELLAS Life Sciences Group has been fully executed, with SELLAS ordered to pay approximately 7.983 million yuan in costs, which has been received in full.
Source: